PYC Therapeutics (ASX:PYC) said it received Safety Review Committee approval in July to escalate dosing in the phase 1b part C multiple ascending dose study in polycystic kidney disease patients to the higher dose group of 2.4 milligrams per kilogram of its drug candidate PYC-003, according to a Wednesday Australian bourse filing.
The company said it also received approval for an open-label extension of the ongoing study to enable continuous dosing of the drug candidate for a period of up to 24 months.
It had AU$669 million of cash on hand as of June 30, per the filing.
PYC Therapeutics' shares rose nearly 2% in recent trading on Wednesday.